AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 251 min read$ANNX

Love Douglas purchased $100K of ANNX

Love Douglas (PRESIDENT AND CEO) purchased 26,065 shares of Annexon, Inc. (ANNX) at $3.83 on 2026-09-24.

Original reporting
SEC EDGAR · Love Douglas
Published Sep 25, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANNX
Bullish
medium confidence
Mentioned
$ANNX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANNXBullishMed
01

Why it matters

The purchase may signal confidence from leadership, prompting short-term buying interest.

02

Market read

CEO's $100K share purchase could influence Annexon's stock momentum.

03

What to watch

Potential upcoming product launches or contracts not disclosed yet.

Relevance 4/10Novelty 7/10Timing: filing posted 2026-09-25

Background

Form 4 filing discloses insider transactions; such filings are primary sources of new information.

Company-level read

Ticker impact

$ANNXBullishMedium confidence
Context

CEO Love Douglas bought 26,065 shares for $99,828.95, increasing his stake to 390,476 shares.

Expected impact

Possible short-term price uptick as market views purchase favorably.

Evidence & confidence

CEO acquisition of ~100k USD is material for a micro‑cap, indicating insider belief in future performance.

Market effects

Sector

Minimal; reflects confidence in Annexon's cybersecurity services sector.

Regional

Limited to US investors tracking insider activity.

Global

Low; no broader market effect.

Counterpoint

What could challenge this read

Insider buying could be a window dressing move, not a genuine signal.

Key entities

  • Company
    Annexon, Inc.

    Cybersecurity firm listed on NASDAQ.

  • Person
    Love Douglas

    President and CEO of Annexon.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANNX insider trading history →

Related articles

AUG 22
$ANNXMed

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.

aol.com3 min
AUG 19
$ANNXMedAI 8/10

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. ARCHER II trial for geographic atrophy enrolled 659 patients, exceeding targets. Tanruprubart for Guillain-Barré syndrome (GBS) is on track for BLA submission in Q4 2026, with positive FORWARD study data. Operations are funded into 2028.

fool.com3 min
AUG 12
$ANNXMed

Annexon Q2 Earnings Call Highlights

Annexon (NASDAQ:ANNX) reported Q2 call highlights for its complement-targeted therapy tanruprubart in Guillain-Barre syndrome, saying patients showed rapid functional gains and ventilator weaning within days, with adverse events linked to GBS complications. The company also added a 24-month endpoint to ARCHER II for vonaprument, with 15-month review expected in Q4 2026 and results in 2027.

yahoo.com5 min
AUG 12
$ANNXMed

Annexon Advances C1q-Targeted Therapies; Tanruprubart BLA Filing And ARCHER II Data On The Horizon

Annexon Biosciences (ANNX) reported Q2 2026 results and clinical updates. It said Phase 3 FORWARD tanruprubart in Guillain-Barre has treated the first 10 U.S. and European patients and expects a Q4 2026 BLA filing. For vonaprument in geographic atrophy, ARCHER II remains on track with Month 15 data in Q4 2026 and final completion in Q3 2027. Q2 R&D was $46.6M, net loss $55.3M. Cash was $209.2M. A $200M credit facility was arranged with $50M drawn.

rttnews.com6 min
AUG 12
$SMCIHighAI 8/10

Super Micro jumps premarket on outlook boost, H&R Block surges

U.S. stock futures edged higher ahead of CPI, with investors watching for signals on the Fed’s rate path. In premarket movers, Super Micro Computer rose over 9% on full-year guidance above expectations. H&R Block gained 13.9% after Q4 adjusted EPS of $2.38 vs $2.31 consensus, revenue $3.95B, and FY27 EPS outlook $6.04-$6.24. Other movers included Owlet, Valens Semiconductor, and Riskified.

investing.com4 min
AUG 12
$ANNXMedAI 8/10

Annexon Biosciences: Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon, Inc. (Nasdaq: ANNX) reported Q2 2026 results and clinical updates. It said tanruprubart GBS data support a Q4 2026 BLA submission, and vonaprument GA Phase 3 ARCHER II is on track with a Month 15 endpoint in Q4 2026 and Month 24 in Q3 2027. Cash was $209.2M at June 30, 2026; net loss was $55.3M. It also secured a $200M credit facility.

finanznachrichten.de7 min